Exelixis (EXEL) Capital Expenditures Growth (5y) (2015 - 2026)
Exelixis (EXEL) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -35.54% |
| Jan 2, 2026 | -45.81% |
| Apr 4, 2025 | -0.06% |
| Sep 27, 2024 | 31.83% |
| Jun 28, 2024 | 40.29% |
| Mar 29, 2024 | 33.25% |
| Dec 29, 2023 | 19.57% |
| Sep 29, 2023 | -20.97% |
| Jun 30, 2023 | 23.71% |
| Mar 31, 2023 | 12.72% |
| Dec 30, 2022 | -14.20% |
| Sep 30, 2022 | 45.85% |
| Jul 1, 2022 | 73.31% |
| Apr 1, 2022 | 211.91% |
| Dec 31, 2021 | 98.59% |
| Oct 1, 2021 | -91.21% |
| Jul 2, 2021 | 169.56% |
| Apr 2, 2021 | 125.46% |
| Apr 3, 2020 | 91.49% |
| Sep 27, 2019 | 80.32% |